SANDOSTATIN® LAR®


Dry vial - microspheres for injection with SUSPENSION VEHICLE
scheduling status
S4
registration number
33/34/0239; 33/34/0240; 33/34/0241; 33/34/0242
What SANDOSTATIN® LAR® contains
SANDOSTATIN LAR 10 mg: Each vial contains 10 mg octreotide free peptide equivalent to 11,2 mg octreotide acetate. SANDOSTATIN LAR 20 mg: Each vial contains 20 mg octreotide free peptide equivalent to 22,4 mg octreotide acetate. SANDOSTATIN LAR 30 mg: Each vial contains 30 mg octreotide free peptide equivalent to 33,6 mg octreotide acetate.
other ingredients
Powder (vial): Poly(DL)-Iactide-co-glycolide, Mannitol, sterilised. SANDOSTATIN suspension vehicle - Solvent (Prefilled syringe): Carmellose sodium, Mannitol (E421), Poloxamer 188, Water for injections.
Therapeutic classification
H01CB02.
© 2026 SAHPRA. ALL RIGHTS RESERVED